ARAV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Jan 2024 @ 16:00):

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States...

Stats
Today's Volume	4.04M
Average Volume	2.24M
Market Cap	2.95M
EPS	$0 ( 2024-03-20 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0528
ATR14	$0.0130 (32.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-10	Petrini Maria Carolina	Buy	400 000	Nonqualified Stock Option (Right to Buy)
2023-04-10	Petrini Maria Carolina	Buy	0
2023-02-01	Mcintyre Gail Frances	Buy	700 000	Stock Option (Right to Buy)
2023-02-01	Geller Robert B.	Buy	400 000	Stock Option (Right to Buy)
2023-02-01	Howard Rudy	Buy	400 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 72 486 477 \| Sell: 119 333

Volume Correlation

Long: 0.29 (neutral)

Short: 0.00 (neutral)

Signal:(20.648) Neutral

Aravive Inc Correlation

10 Most Positive Correlations
ALXN	0.865
GENQ	0.848
BMAQ	0.847
ATNX	0.845
ROIV	0.843
TCMD	0.84
FXCO	0.84
OTEC	0.839
BRAC	0.839
ACAB	0.838

10 Most Negative Correlations
EPSN	-0.867
GRIN	-0.853
MDGS	-0.853
FJP	-0.843
RFDI	-0.841
EWJV	-0.84
ALKS	-0.84
RNEM	-0.839
IFV	-0.837
PIII	-0.835

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aravive Inc Correlation - Currency/Commodity

-0.64
( weak negative )

-0.72
( moderate negative )

0.00
( neutral )

-0.36
( neutral )

-0.82
( strong negative )

0.20
( neutral )

Aravive Inc Financials

Annual	2022
Revenue:	$9.14M
Gross Profit:	$-57.80M (-632.60 %)
EPS:	$-2.22

Q3	2023
Revenue:	$2.76M
Gross Profit:	$-5.97M (-216.76 %)
EPS:	$0.280

Q2	2023
Revenue:	$1.27M
Gross Profit:	$-9.52M (-746.94 %)
EPS:	$0.240

Q1	2023
Revenue:	$1.49M
Gross Profit:	$-14.42M (-967.40 %)
EPS:	$-1.080

Financial Reports:

No articles found.

Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.